- Research article
- Open Access
- Open Peer Review
The non-syndromic familial thoracic aortic aneurysms and dissections maps to 15q21 locus
© Keramati et al; licensee BioMed Central Ltd. 2010
- Received: 10 September 2009
- Accepted: 11 October 2010
- Published: 11 October 2010
Thoracic aortic aneurysms and dissections (TAAD) is a critical condition that often goes undiagnosed with fatal consequences. While majority of the cases are sporadic, more than 20% are inherited as a single gene disorder. The most common familial TAA is Marfan syndrome (MFS), which is primarily caused by mutations in fibrillin-1 (FBN1) gene. Patients with FBN1 mutations are at higher risk for dissection compared to other patients with similar size aneurysms.
Fifteen family members were genotyped using Affymetrix-10K genechips. A genome-wide association study was carried out using an autosomal dominant model of inheritance with incomplete penetrance. Mutation screening of all exons and exon-intron boundaries of FBN1 gene which reside near the peak Lod score was carried out by direct sequencing.
The index case presented with agonizing substernal pain and was found to have TAAD by transthoracic echocardiogram. The family history was significant for 3 first degree relatives with TAA. Nine additional family members were diagnosed with TAA by echocardiography examinations. The affected individuals had no syndromic features. A genome-wide analysis of linkage mapped the disease gene to a single locus on chromosome 15q21 with a peak Lod score of 3.6 at fibrillin-1 (FBN1) gene locus (odds ratio > 4000:1 in favour of linkage), strongly suggesting that FBN1 is the causative gene. No mutation was identified within the exons and exon-intron boundaries of FBN1 gene that segregated with the disease. Haplotype analysis identified additional mutation carriers who had previously unknown status due to borderline dilation of the ascending aorta.
A familial non-syndromic TAAD is strongly associated with the FBN1 gene locus and has a malignant disease course often seen in MFS patients. This finding indicates the importance of obtaining detailed family history and echocardiographic screening of extended relatives of patients with non-syndromic TAAD to improve the outcome. In addition, association of non-syndromic TAAD with the Marfan disease gene locus poses the question whether secondary prevention strategies employed for Marfan syndrome patients should be applied to all patients with familial TAAD.
- Mutation Carrier
- Marfan Syndrome
- Thoracic Aortic Aneurysm
- Intronic Mutation
- Thoracic Aneurysm
Thoracic aortic aneurysms and dissections (TAAD) is a lethal condition with a rising incidence [1, 2]. Although this condition often occurs sporadically, about one out of every 5 cases is familial. This includes syndromic forms of the disease, including Marfan syndrome (MFS) and the less commonly seen Loeys-Dietz syndrome as well as the non-syndromic thoracic aortic aneurysm. The mode of inheritance in most cases is consistent with autosomal dominant with incomplete penetrance. It is a heterogeneous disorder for which more than 4 loci have been mapped [4–7].
Marfan syndrome is a connective tissue disorder that affects multiple organs including cardiovascular and skeletal systems . It is often inherited as an autosomal dominant disorder caused by FBN1 gene mutation [8–12]. Its most lethal complication is aortic aneurysm, a malignant disorder which results in early onset dissection and death . Whether FBN1 mutation can cause non-syndromic familial aneurysm and more importantly if the disease course is equally malignant is not known. Absence of syndromic features in FBN1 mutation carriers may not have implications for disease screening. This screening may include obtaining detailed family and an echocardiographic examination. In addition, the family history and the disease course in the family members with advanced disease and complications may impact the future planning for at risk family members. With the advent of cost effective high throughput sequencing techniques, mutation screening of patients with thoracic aortic aneurysms for known genes such as FBN1 may become part of the routine clinical workup.
In the current study, we identified a large three-generation family with multiple members affected by early onset TAAD in absence of syndromic features. A genome-wide analysis of linkage was carried out to map the disease gene.
The research protocol was approved by the institutional review boards of all participating institutions. All study participants provided written informed consent for clinical and genetic studies. Detailed family history was obtained and extensive physical examination by a clinical geneticist was carried out. Family members were examined for musculoskeletal, pulmonary, and dermatological features of MFS based on Ghent nosology. Ophthalmologic and echocardiographic examinations were carried out by an ophthalmologist and a cardiologist, respectively. For echocardiographic evaluation of the aneurysms, diameters of the aorta at the sinus of valsalva, the supra-aortic ridge, and the aortic root were measured from cross-sectional echocardiography images in the parasternal long-axis. Individuals were identified as affected if they had an aneurysm (diameter ≥3.6 cm at the aortic root or supra-aortic ridge level) or dissection of the ascending thoracic aorta. MRI examinations of the lumbosacral region were carried out on limited number of patients with thoracic aneurysms. Blood samples were collected from family members. Genomic DNA was isolated from 15 family members.
Genotyping and Analysis of Linkage
Thirteen family members were called as affected (2 were deceased), 2 as unaffected and 2 as unknown. Affymetrix 10K DNA genechip arrays were used to genotype > 10,000 SNPs across the genome in all 15 living family members.
Allele frequencies for each SNP were mean allele frequencies of 20 unrelated unaffected Iranian (ethnically matched) and penetrance was set at 90%. Multipoint analysis of linkage with Genehunter was used for the genome scan analysis.
Sequence variation detection and functional analysis
All 66 exons and exon-intron boundaries of FBN1 were amplified by PCR and were evaluated using direct dye-termination sequencing. Sequences were evaluated using the sequencer software and were interpreted independently by two lab members. Complementary strands were sequenced to confirm potential substitutions. Skin biopsies were obtained as part of the clinical workup by the local dermatologists and were evaluated by the local diagnostic laboratory using immunocytochemistry.
Mapping of the Locus
Construction of the 15q haplotype with SNPS revealed recombinations immediately prior to rs668842 and after rs1072994, refining the linked interval to less than 500 kb. Haplotype analysis indicated the segregation of the disease haplotype in two family members whose ascending aorta were assessed as borderline dilated, thus identifying two individuals with unknown status as mutation carriers.
Mutation analysis and FBN1 expression
No disease segregating mutation was identified in exons or exon-intron boundaries of FBN1 genes. No other intronic mutation was identified which could potentially affect the splicing. A total of 5 novel and evolutionarily highly conserved intronic mutations were identified which did not segregate with the disease. Haplotype analysis of the affected individuals within this kindred showed that all the identified intronic mutations reside on unlinked/non-disease chromosomes and did not refine the linked interval.
The results from skin biopsies of 3 family members with TAAD were reported as suggestive for Marfan syndrome based on abnormal expression of FBN1 in fibroblasts. No images were provided to us by the laboratory.
Thoracic aortic aneurysms and dissections in patients with MFS has very poor outcome. Identification of at risk individuals prior to an event is therefore of great importance. In the current study, genome-wide analysis in a family with non-syndromic TAAD has mapped the disease gene to MFS disease gene locus. Although mutation carriers in this family did not have syndromic features of the Marfan syndrome, the aortic disease in many of the affected family members had a malignant course. This finding suggests that autosomal dominant non-syndromic TAAD may be associated with FBN1 gene mutation and implicates the necessity of echocardiographic screening of the relatives of patients with familial TAAD.
Acute aortic aneurysm is an uncommon but potentially catastrophic illness with an incidence of approximately 2.9/100,000/yr . Predisposing factors are either acquired such as trauma, caused by complex traits like, hypertension, and bicuspid aortic valve or inherited such as in Marfan syndrome. Among these, patients with Marfan syndrome are especially at high risk for aortic dissection of the ascending aorta at a relatively young age . Patients with familial aneurysms also tend to be younger and have higher rates of dissection compared to those with sporadic aneurysms , signifying the importance of early screening of at risk family members. An analysis of a large database of patients treated at Yale-New Haven Hospital  has shown that patients with familial autosomal dominant thoracic aortic aneurysms present with complications at much younger ages (mean 57 years compared to sporadic cases (mean age 64 years).
Although non-syndromic familial TAAD is a hereditary disorder, genetic causes of it remain vastly unknown. An investigation of the families of 158 patients referred for surgical repair of thoracic aortic aneurysms or dissections found that first-degree relatives of probands had a higher risk (risk ratio [RR] 1.8 for fathers and sisters, RR 10.9 for brothers) of thoracic aortic aneurysms or sudden death compared with control subjects .
At least four different loci have been thus far mapped for familial non-syndromic thoracic aortic aneurysms. Mutations in transforming growth factor-beta receptor type II have been associated with some cases of familial thoracic aortic aneurysms [5, 6]. Mutations in myosin heavy chain (MYH11), a smooth muscle cell-specific contractile protein, have been identified in familial TAAD associated with patent ductus arteriosus (PDA) linked to 16p12.2-12.13. However, some families have mapped to neither of these loci suggesting additional loci. We provide a strong evidence for linkage of non-syndromic familial thoracic aneurysms and dissections to FBN1 locus. Although a unique phenotype of aortic dissections involving both the ascending and descending aorta along has been mapped to chromosome 15q in a single kindred , we report here for the first time linkage of a large family with isolated TAAD to MFS gene locus. All affected individuals and none among the unaffecteds carry the disease haplotype. Association between FBN1 mutation and familial non-syndromic aortic aneurysm has been previously reported . In the reported kindred, FBN1 mutation segregated in most but not all family members and there were mutation carriers who were unaffected. Moreover, some affected individuals had one or another musculoskeletal finding of Marfan syndrome. FBN1 mutation has been also reported in sporadic cases of non-syndromic thoracic aneurysm . MFS is a pleiotropic disease and many of its phenotypes may be absent in one individual and be present in a close relative. Since the extended families of patients with TAAD were not examined for the musculoskeletal phenotypes of Marfan syndrome, diagnosis of MFS cannot be definitively excluded. Moreover, the proof of causality was based on a single mutation and not genetic linkage analysis.
In this study, we did not identify any disease segregating mutation in the FBN1 gene in the affected individuals. Although there may be an unidentified disease causing mutation within the linked interval unrelated to FBN1 gene, the small size of the linked interval and the significant lod score that peaks at FBN1 gene locus rather indicate that disease in this kindred is caused an unidentified variation within this gene. It is a general consensus that absence of FBN1 mutation does not exclude diagnosis because of high rates of false negative results, likely due to presence of intronic mutations. In addition, identification of nonsynonymous mutations in absence of significant linkage to the disease locus or clinical criteria is not considered diagnostic for MFS. There is increasing controversy about significance of many of the identified FBN1 mutations. FBN1 mutations can be found in many other conditions that may or may not overlap with Marfan syndrome such as skin and skeletal findings (Shprintzen-Goldberg syndrome), syndrome of mitral valve prolapse, myopia, borderline aortic enlargement, skin and skeletal findings, Marfanoid habitus and isolated ectopia lentis. In contrast analysis of linkage remains one of the most reliable molecular methods for diagnosis of Marfan syndrome. Most importantly, the lod-1 interval in this kindred contains only two other genes (SLC12A1, DYUT) which because of their tissue distributions and functions cannot be causative gene for TAAD.
We demonstrate in this study the largest reported kindred with non-syndromic TAAD that unambiguously links to 15q21, the locus for FBN1 gene. We conclude that in genetic study of non-syndromic TAAD, FBN1 gene should be considered as one of the candidate genes. Moreover, the malignant course of the disease in this kindred underscores the importance of echocardiographic screening in extended relatives of patients with familial non-syndromic TAAD. Finally, it raises an important question to whether secondary prevention strategies employed for Marfan syndrome patients which include angiotensin converting enzyme inhibitors should be also examined in patients with early onset familial TAAD.
We thank members of the kindred for their invaluable participation in this project. This research project is supported in part by an NIH 1R01HL094574-01 award (to A.M.)
- Biddinger A, Rocklin M, Coselli J, Milewicz D: Familial thoracic aortic dilatations and dissections: a case control study. J Vasc Surg. 1997, 25 (3): 506-511. 10.1016/S0741-5214(97)70261-1.View ArticlePubMedGoogle Scholar
- Olsson C, Thelin S, Ståhle E, Ekbom A, Granath F: Thoracic aortic aneurysm and dissection: increasing prevalence and improved outcomes reported in a nationwide population-based study of more than 14,000 cases from 1987 to 2002. Circulation. 2006, 114 (24): 2611-2618. 10.1161/CIRCULATIONAHA.106.630400.View ArticlePubMedGoogle Scholar
- Milewicz D, Chen H, Park E, Petty E, Zaghi H, Shashidhar G, Willing M, Patel V: Reduced penetrance and variable expressivity of familial thoracic aortic aneurysms/dissections. Am J Cardiol. 1998, 82 (4): 474-479. 10.1016/S0002-9149(98)00364-6.View ArticlePubMedGoogle Scholar
- Biggin A, Holman K, Brett M, Bennetts B, Adès L: Detection of thirty novel FBN1 mutations in patients with Marfan syndrome or a related fibrillinopathy. Hum Mutat. 2004, 23 (1): 99-10.1002/humu.9207.View ArticlePubMedGoogle Scholar
- Loeys B, Schwarze U, Holm T, Callewaert B, Thomas G, Pannu H, De Backer J, Oswald G, Symoens S, Manouvrier S, et al: Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med. 2006, 355 (8): 788-798. 10.1056/NEJMoa055695.View ArticlePubMedGoogle Scholar
- Pannu H, Fadulu V, Chang J, Lafont A, Hasham S, Sparks E, Giampietro P, Zaleski C, Estrera A, Safi H, et al: Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation. 2005, 112 (4): 513-520. 10.1161/CIRCULATIONAHA.105.537340.View ArticlePubMedGoogle Scholar
- Murdoch J, Walker B, Halpern B, Kuzma J, McKusick V: Life expectancy and causes of death in the Marfan syndrome. N Engl J Med. 1972, 286 (15): 804-808. 10.1056/NEJM197204132861502.View ArticlePubMedGoogle Scholar
- Kainulainen K, Pulkkinen L, Savolainen A, Kaitila I, Peltonen L: Location on chromosome 15 of the gene defect causing Marfan syndrome. N Engl J Med. 1990, 323 (14): 935-939. 10.1056/NEJM199010043231402.View ArticlePubMedGoogle Scholar
- Dietz H, Cutting G, Pyeritz R, Maslen C, Sakai L, Corson G, Puffenberger E, Hamosh A, Nanthakumar E, Curristin S: Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991, 352 (6333): 337-339. 10.1038/352337a0.View ArticlePubMedGoogle Scholar
- Tsipouras P, Sarfarazi M, Devi A, Weiffenbach B, Boxer M: Marfan syndrome is closely linked to a marker on chromosome 15q1.5----q2.1. Proc Natl Acad Sci USA. 1991, 88 (10): 4486-4488. 10.1073/pnas.88.10.4486.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee B, Godfrey M, Vitale E, Hori H, Mattei M, Sarfarazi M, Tsipouras P, Ramirez F, Hollister D: Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes. Nature. 1991, 352 (6333): 330-334. 10.1038/352330a0.View ArticlePubMedGoogle Scholar
- Dietz H, Pyeritz R, Hall B, Cadle R, Hamosh A, Schwartz J, Meyers D, Francomano C: The Marfan syndrome locus: confirmation of assignment to chromosome 15 and identification of tightly linked markers at 15q15-q21.3. Genomics. 1991, 9 (2): 355-361. 10.1016/0888-7543(91)90264-F.View ArticlePubMedGoogle Scholar
- Faivre L, Collod-Beroud G, Loeys B, Child A, Binquet C, Gautier E, Callewaert B, Arbustini E, Mayer K, Arslan-Kirchner M, et al: Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am J Hum Genet. 2007, 81 (3): 454-466. 10.1086/520125.View ArticlePubMedPubMed CentralGoogle Scholar
- Mészáros I, Mórocz J, Szlávi J, Schmidt J, Tornóci L, Nagy L, Szép L: Epidemiology and clinicopathology of aortic dissection. Chest. 2000, 117 (5): 1271-1278. 10.1378/chest.117.5.1271.View ArticlePubMedGoogle Scholar
- Hagan P, Nienaber C, Isselbacher E, Bruckman D, Karavite D, Russman P, Evangelista A, Fattori R, Suzuki T, Oh J, et al: The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA. 2000, 283 (7): 897-903. 10.1001/jama.283.7.897.View ArticlePubMedGoogle Scholar
- Coady M, Davies R, Roberts M, Goldstein L, Rogalski M, Rizzo J, Hammond G, Kopf G, Elefteriades J: Familial patterns of thoracic aortic aneurysms. Arch Surg. 1999, 134 (4): 361-367. 10.1001/archsurg.134.4.361.View ArticlePubMedGoogle Scholar
- Zhu L, Vranckx R, Khau Van Kien P, Lalande A, Boisset N, Mathieu F, Wegman M, Glancy L, Gasc J, Brunotte F, et al: Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet. 2006, 38 (3): 343-349. 10.1038/ng1721.View ArticlePubMedGoogle Scholar
- Tran-Fadulu V, Chen J, Lemuth D, Neichoy B, Yuan J, Gomes N, Sparks E, Kramer L, Guo D, Pannu H, et al: Familial thoracic aortic aneurysms and dissections: three families with early-onset ascending and descending aortic dissections in women. Am J Med Genet A. 2006, 140 (11): 1196-1202.View ArticlePubMedGoogle Scholar
- Francke U, Berg M, Tynan K, Brenn T, Liu W, Aoyama T, Gasner C, Miller D, Furthmayr H: A Gly1127Ser mutation in an EGF-like domain of the fibrillin-1 gene is a risk factor for ascending aortic aneurysm and dissection. Am J Hum Genet. 1995, 56 (6): 1287-1296.PubMedPubMed CentralGoogle Scholar
- Milewicz D, Michael K, Fisher N, Coselli J, Markello T, Biddinger A: Fibrillin-1 (FBN1) mutations in patients with thoracic aortic aneurysms. Circulation. 1996, 94 (11): 2708-2711.View ArticlePubMedGoogle Scholar
- Sood S, Eldadah Z, Krause W, McIntosh I, Dietz H: Mutation in fibrillin-1 and the Marfanoid-craniosynostosis (Shprintzen-Goldberg) syndrome. Nat Genet. 1996, 12 (2): 209-211. 10.1038/ng0296-209.View ArticlePubMedGoogle Scholar
- Dietz H: Molecular etiology, pathogenesis and diagnosis of the Marfan syndrome. Prog Pediatr Cardiol. 1996, 5: 159-166. 10.1016/1058-9813(96)00161-0.View ArticleGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2350/11/143/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.